Cambridge Researchers Identify Three Distinct Biological Subtypes of Severe Pneumonia, Explaining Variable ICU Outcomes
核心洞察
Severe pneumonia (搜索) comprises three distinct biological subtypes, or "pneumotypes," that are indistinguishable by standard clinical presentation but strongly linked to patient recovery trajectories.
The most common subtype (49% of cases) features immune suppression and lung lining damage with minimal inflammation, potentially explaining why anti-inflammatory therapies fail or harm some patients.
A balanced immune response subtype (23% of cases) was associated with the fastest recovery and shortest ventilator time, despite initially comparable illness severity.
Researchers at the University of Cambridge have identified three distinct biological subtypes of severe pneumonia (搜索), a discovery that helps explain why patients in intensive care units (ICUs) who appear clinically similar can experience dramatically different outcomes. The findings, published today in Nature Communications, challenge the conventional "one-size-fits-all" approach to treating severe pneumonia and point toward a future of tailored therapeutics.
Pneumonia is the most common infectious cause of death worldwide, responsible for an estimated 2.5 million deaths annually. Severe pneumonia (搜索) accounts for six in ten infections managed in intensive care, where some patients recover quickly while others remain critically ill for weeks or die.
"Even though we're able to treat the initial infection, many patients with severe pneumonia (搜索) still struggle to come off the ventilator and can develop lung failure. Therapies to tackle inflammation in the lungs have had mixed results in clinical trials—some suggest they are beneficial, others that they're harmful," said Dr. Andrew Conway Morris from the Department of Medicine at the University of Cambridge and ICU consultant at Addenbrooke's Hospital.
Beyond Clinical Syndromes to Underlying Biology
The current approach to classifying patients relies on clinical syndromes such as sepsis and acute respiratory distress syndrome, without examining the underlying biological mechanisms. Dr. Conway Morris argued that the critical question should shift from "Does this patient have pneumonia?" to "What's the inflammatory pattern in this patient's lungs?"
To answer this, the Cambridge team recruited patients admitted with suspected severe pneumonia (搜索) to the ICU at Addenbrooke's Hospital, part of Cambridge University Hospitals NHS Foundation Trust. Rather than relying solely on blood tests or imaging, the researchers analyzed immune cells, inflammatory signals, and gene activity in fluid taken directly from the patients' lungs.
This approach revealed three distinct biological types—termed "pneumotypes"—none of which could be reliably detected using standard blood tests, despite being strongly linked to patient recovery.
The Three Pneumotypes
The most common pneumotype, accounting for nearly half (49%) of cases, was characterized by immune suppression, significant damage to the lining of the lungs, and bleeding in the alveoli. Notably, this subtype showed fewer signs of inflammation, which may explain why treatments targeting inflammation can fail or even cause harm in some patients.
The second pneumotype, representing just under a quarter (23%) of cases, featured a balanced immune response and active repair of lung damage. Patients with this subtype were most likely to recover faster and required the shortest time on mechanical ventilation, even though they initially presented with illness severity comparable to other patients.
The most dangerous pneumotype—the one that most closely resembles "classic" pneumonia—was marked by severe and persistent inflammation, with a flood of immature immune cells in the lungs. These patients spent the longest time on mechanical ventilation and endured prolonged critical illness. The research team suggested this group may be most likely to respond to anti-inflammatory therapies.
Implications for Clinical Trials and Treatment
Dr. Mark Jeffrey from the Department of Medicine at the University of Cambridge, the study's first author, emphasized the clinical implications: "Even though, on the surface, all of the patients seemed to have similar types of pneumonia, with comparable illness severity, oxygen levels and clinical diagnoses, their outcomes were very different."
"It was only when we drilled down and looked at patterns of inflammation that the differences became apparent. Severe pneumonia (搜索) is not a single disease, but several biologically distinct conditions that happen to look alike. This helps explain why 'one-size-fits-all' treatments—including some immune-modulating drugs—have often failed in clinical trials," Dr. Jeffrey added.
The tests currently used to determine pneumotypes are too complex for rapid bedside classification, but the researchers hope to develop a simplified tool that could enable patient stratification and ultimately guide tailored treatment decisions.
Dr. Vilas Navapurkar from the John Farman Intensive Care Unit at Addenbrooke's Hospital noted the potential clinical impact: "If we know which subtype of pneumonia an individual has, we can potentially tailor their treatment more precisely, boosting the immune response in some, while calming harmful inflammation in others. This has the potential to help critically ill patients, reduce deaths from pneumonia, shorten ICU stays and cut unnecessary antibiotic use."
The study was funded by Addenbrooke's Charitable Trust, the National Institute for Health and Care Research Cambridge Biomedical Research Centre, and The Forster Foundation.